These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 8205090)
1. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. van der Jagt RH; Pari G; McDiarmid SA; Boisvert DM; Huebsch LB Bone Marrow Transplant; 1994 Feb; 13(2):203-7. PubMed ID: 8205090 [TBL] [Abstract][Full Text] [Related]
2. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Stockschläder M; Kalhs P; Peters S; Zeller W; Krüger W; Kabisch H; Lechner K; Zander A Bone Marrow Transplant; 1993 Oct; 12(4):357-62. PubMed ID: 8275035 [TBL] [Abstract][Full Text] [Related]
3. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281 [TBL] [Abstract][Full Text] [Related]
4. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786 [TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning. Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862 [TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700 [TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650 [TBL] [Abstract][Full Text] [Related]
8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013 [TBL] [Abstract][Full Text] [Related]
12. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486 [TBL] [Abstract][Full Text] [Related]
13. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057 [TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947 [TBL] [Abstract][Full Text] [Related]
15. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682 [TBL] [Abstract][Full Text] [Related]
16. [Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation]. López J; Cancelas JA; Valiño JM; García-Laraña J; Sastre JL; Pérez-Oteyza J; Cerveró C; García-Avello A; Cabezudo E; Arranz MI Med Clin (Barc); 1994 Apr; 102(13):485-8. PubMed ID: 8208006 [TBL] [Abstract][Full Text] [Related]
17. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039 [TBL] [Abstract][Full Text] [Related]
18. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938 [TBL] [Abstract][Full Text] [Related]
19. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]